Evaxion reports 89% immune response rate for personalized melanoma vaccine in phase‑2 trial
Evaxion A/S presented new biomarker data from its phase‑2 trial of the personalized vaccine EVX‑01 in advanced melanoma. The data showed that 89% of the vaccine targets triggered an immune response and that neoantigen‑specific T‑cell responses were detected ex vivo, mainly CD4+ cells with CD8+ responses in half of the patients. A statistical analysis found a significant association (p < 0.001) between the AI‑Immunology™ platform’s predictions and the observed T‑cell responses. The results were shared at the SITC 2026 Annual Meeting in Phoenix.
Why it matters
The company says the findings validate the predictive power of its AI‑Immunology™ platform and de‑risk the EVX‑01 program, which could support future partnerships or regulatory progress.
Key facts
- 189% of vaccine targets triggered an immune response. stocktitan.net
- 2Neoantigen‑specific T‑cell responses were detected ex vivo, dominated by CD4+ cells, with CD8+ responses in half of patients. stocktitan.net
- 3A significant association (p < 0.001) was found between AI‑Immunology™ predictions and actual T‑cell responses. stocktitan.net
- 4The data were presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting in Phoenix, Arizona. stocktitan.net
- 5Evaxion described the results as further validation of its AI‑Immunology™ platform. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.